Schall Law Firm Encourages PepGen Investors to Join Class Action Lawsuit

Class Action Alert for PepGen Inc. Investors

The Schall Law Firm, a prominent litigation firm specializing in shareholder rights, has issued a reminder to investors regarding a class action lawsuit initiated against PepGen Inc. This lawsuit highlights serious allegations of securities fraud related to the company's recent activities in the pharmaceutical sector.

Background of the Case

Investors who acquired shares of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024, and March 3, 2025, are particularly encouraged to participate in this legal action. The lawsuit stems from purported violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5, established by the U.S. Securities and Exchange Commission. Allegations suggest that the company made false and misleading statements regarding their drug candidate, PGN-EDO51, claiming it was safer and more effective than it actually was.

The Claims Against PepGen

According to the complaint, the CONNECT2 study, which was pivotal for the FDA approval of PGN-EDO51, was not only deficient, but also posed significant risks to participants involved in the study. As a result of these misleading representations, many investors experienced considerable financial losses when the real situation regarding the drug and the associated studies came to light, leading to a decline in the company’s stock value.

Opportunity for Shareholders

The Schall Law Firm urges all affected shareholders to express their interest in participating in this class action before the deadline of August 8, 2025. Investors can contact Brian Schall directly at 310-301-3335 or visit the firm’s website for more information on how to participate. It is critical to note that until the class is officially certified, individuals who choose not to act may remain unrepresented in this case.

By joining this class action, investors have the opportunity to seek recovery for their losses due to the alleged fraudulent activities by PepGen Inc. The Schall Law Firm has a proven track record of representing investors globally in securities class action lawsuits and is committed to protecting shareholder interests.

Holistic Approach to Investor Rights

Investors involved in this case can benefit not only from potential financial restitution but also from a broader movement towards accountability in corporate governance. The allegations against PepGen highlight an unsettling trend in the pharmaceutical industry, where the pressure to deliver results and innovate can sometimes obscure ethical responsibilities and jeopardize investor trust.

Educational resources are available through the Schall Law Firm’s platforms, shedding light on shareholders' rights and the implications of corporate misconduct. This lawsuit against PepGen is particularly critical as it addresses systemic issues within biotech companies and aims to safeguard the interests of individuals who put their faith — and finances — into these ventures.

Conclusion

In conclusion, the upcoming class action lawsuit serves not only as an opportunity for those who invested in PepGen Inc. but also as a reminder of the importance of transparency in corporate communications. Potential investors should exercise diligence and stay informed regarding their rights and any developments in the case. Joining the class before the deadline could safeguard their investments and ensure their voices are heard in the ongoing dialogue about corporate accountability and governance.

For further inquiries, please do not hesitate to reach out directly to the Schall Law Firm, either through their website or by phone — legal representation is just a step away.